Q Fever Surveillance in Ruminants, Thailand, 2012

although its mechanism of action against HCV and HEV is uncertain.Data are limited on the use of ribavirin in patients with chronic hepatitis E and hematologic malignancies (10).The outcome for our patient suggests that ribavirin might be useful for treating hepatitis E in such patients.In conclusion, all patients with hepatitis of unknown origin should be tested for HEV, in particular, immunocompromised patients, because they are at risk of acquiring chronic hepatitis and having an adverse outcome.Ribavirin appears to be efficacious in treating hepatitis E and should be considered for any immunocompromised person who has viremia 3 months after acute infection.